A new AI-powered test offers more accurate prediction of breast cancer recurrence risk

A new study published in the journal npj Breast Cancer demonstrates that an artificial intelligence (AI) model offers more accurate predictions of recurrence risk in patients with early-stage breast cancer than the widely used 21-gene Recurrence Score. This research, conducted by a team from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences, specifically targets hormone receptor-positive (HR+) and HER2-negative disease, the most common subtype of breast cancer, which accounts for about half of all breast cancer cases in the United States.

≈